Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Slides:

Advertisements

Similar presentations

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Advertisements

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Intracellular Pathogens Extracellular Pathogens

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Adverse Renal Effects of Immune Checkpoint Inhibitors:

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Volume 199, Issue 5, Pages (May 2018)

Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD,

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review Am J Nephrol 2017;45: DOI: / Fig. 1. CTLA-4 and PD-1.

Mechanisms of Drug-Induced Allergy

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 6 Combination therapy for HCC

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

It Takes Two to Tango Immunity

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Cyclosporine in the Treatment of Dermatologic Disease: An Update

Hiding in Plain Sight: How Cancer Evades the Immune System

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Nat. Rev. Rheumatol. doi: /nrrheum

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Mechanisms of immune escape in the tumor microenvironment.

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Dendritic cells: regulators of hepatic immunity or tolerance?

The Other Face of Chimeric Antigen Receptors

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Urol. doi: /nrurol

Pathogenesisof PsA and RA

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Santhi Voora, Deborah B. Adey American Journal of Kidney Diseases

Cell-mediated immunity Regulation of the immune response

Sterile Inflammation Fuels Gastric Cancer

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Therapy of Alopecia Areata: On the Cusp and in the Future

A: Spindle cells are arranged in sheets and short fascicles admixed with plasma cells (hematoxylin and eosin stain, ×400). A: Spindle cells are arranged.

Releasing the Brakes on Cancer Immunotherapy

Graph demonstrates the difference in negative pressure generated by a negative pressure bottle in relation to the volume of fluid removed while performing.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Figure 4 Molecular signalling and immunological

A schematic presentation of secreted, endocytic, and signaling pattern-recognition receptors. A schematic presentation of secreted, endocytic, and signaling.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Computed tomography shows the small bowel abnormally localized in the upper left portion of the abdomen. An appreciable thin membrane, denoted by an arrow,

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Presentation transcript:

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex; PD-1/PD-2, programmed cell death-1/-2; PD-LI/PD-L2, programmed cell death receptor-1/-2 ligand; TCR, T cell receptor. Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex; PD-1/PD-2, programmed cell death-1/-2; PD-LI/PD-L2, programmed cell death receptor-1/-2 ligand; TCR, T cell receptor. Tanvir F. Kabir et al. TOJ 2018;18:370-376 Copyright © 2018 by Ochsner Clinic Foundation